ATC Group: L01EC04 Tovorafenib

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01EC04 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01E Protein kinase inhibitors
4 L01EC B-Raf serine-threonine kinase (BRAF) inhibitors
5 L01EC04

Active ingredients in L01EC04

Active Ingredient

Tovorafenib is a central nervous system (CNS) penetrant, selective small molecule Type II RAF kinase inhibitor of mutant BRAF V600E, wild-type BRAF, and wild-type CRAF kinases, including RAF monomers and dimers and BRAF fusion, suppressing activation of the mitogen-activated protein kinase (MAPK) pathway.

Related product monographs

Document Type Information Source  
 OJEMDA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 OJEMDA Powder for oral suspension MPI, EU: SmPC European Medicines Agency (EU)
 OJEMDA Tablet / Oral suspension MPI, US: SPL/PLR FDA, National Drug Code (US)

United States medicines

Medicines classified under this ATC code globally

Austria (AT)

Lithuania (LT)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.

Go to ATC index
⇈